Abacavir
- Generic Name
- Abacavir
- Brand Names
- Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N6O
- CAS Number
- 136470-78-5
- Unique Ingredient Identifier
- WR2TIP26VS
- Background
Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
- Indication
Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Characterization of Acute and Recent HIV-1 Infections in Zurich.
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 800
- Registration Number
- NCT00537966
- Locations
- 🇨🇭
University of Zurich, Zurich, Switzerland
Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity
- Conditions
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2010-01-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1806
- Registration Number
- NCT00340080
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC
- Conditions
- Interventions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Hospital de Granollers
- Target Recruit Count
- 75
- Registration Number
- NCT00338390
- Locations
- 🇪🇸
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
🇪🇸Hospital Sierrallana, Torrelavega, Santander, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Spain
Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In HIV Infected Subjects
- Conditions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00320307
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.
- Conditions
- First Posted Date
- 2005-12-28
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT00270556
When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)
- Conditions
- Interventions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2013-12-04
- Target Recruit Count
- 300
- Registration Number
- NCT00234091
- Locations
- 🇰🇭
National Pediatric Hosp., Cambodia CIPRA CRS, Phnom Penh, Cambodia
🇰🇭Social Health Clinic, Cambodia CIPRA CRS, Phnom Penh, Cambodia
🇹🇭Prapokklao Hosp. CIPRA CRS, Chantaburi, Thailand
Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 21
- Registration Number
- NCT00214890
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸UCI, Irvine, California, United States
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00192660
- Locations
- 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE)
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 80
- Registration Number
- NCT00143702
- Locations
- 🇨🇦
Positive Care Clinic, Toronto, Ontario, Canada
🇨🇦St. Paul's Hospital, Vancouver, British Columbia, Canada
Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2004-02-23
- Last Posted Date
- 2010-08-12
- Target Recruit Count
- 350
- Registration Number
- NCT00078247
- Locations
- 🇺🇬
Makerere University Medical School, Kampala, Uganda
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.